What happened
On 6 October 2026 the UK Government published its formal response accepting in full all 44 recommendations of the National Commission into the Regulation of AI in Healthcare (commission report published 10 September). The response commits the UK to a new proportionate, risk- and lifecycle-based framework for AI-enabled medical devices, shifting from one-off pre-market assessment to continuous real-world monitoring. The MHRA simultaneously opened applications for AI Airlock Phase 3, its regulatory sandbox for AI-enabled medical devices (with three years of additional funding), focused on post-market surveillance and lifecycle regulation. Concrete steps: MHRA draft guidance by December 2026 on managing post-approval changes to adaptive AI medical devices; consultation next year on how to qualify and classify AI-enabled devices; exploration of staged authorisation pathways; implementation roadmap by Spring 2027.
Why it matters
This is the UK's most concrete shift in AI-medtech regulation: it signals AI-enabled medical devices will face lifecycle/continuous-monitoring obligations rather than a single-point pre-market assessment, and gives developers a defined sandbox (AI Airlock Phase 3) for post-market surveillance evidence. Organisations deploying or developing AI medical devices in the NHS must plan for ongoing monitoring, change-management reporting, and updated classification rules from 2027.
Action needed
AI-enabled medical device developers should consider applying to MHRA AI Airlock Phase 3 (webinar 22 October 2026; first wave of innovators selected November 2026) and prepare for the MHRA's draft guidance on post-approval change management due December 2026 plus the upcoming qualification/classification consultation.